Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.26.5 (
RNase P
)
1,348
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
N
6
-Methyladenosine (m
6
A), the most prevalent internal modification associated with eukaryotic mRNAs, influences many steps of mRNA metabolism, including splicing, export, and translation, as well as stability. Recent studies have revealed that m
6
A-containing mRNAs undergo one of two distinct pathways of rapid degradation: deadenylation via the
YT521-B
homology (YTH) domain-containing family protein 2 (YTHDF2; an m
6
A reader protein)-CCR4/NOT (deadenylase) complex or endoribonucleolytic cleavage by the YTHDF2-HRSP12-ribonuclease (RNase) P/mitochondrial RNA-processing (MRP) (endoribonuclease) complex. Some m
6
A-containing circular RNAs (circRNAs) are also subject to endoribonucleolytic cleavage by YTHDF2-HRSP12-
RNase P
/MRP. Here, we highlight recent progress on the molecular mechanisms underlying rapid mRNA degradation via m
6
A and describe our current understanding of the dynamic regulation of m
6
A-mediated mRNA decay through the crosstalk between m
6
A (or YTHDF2) and other cellular factors.
...
PMID:Molecular Mechanisms Driving mRNA Degradation by m
6
A Modification. 3196 9
